• Tue news: Regeneron fails to block Eylea biosimilar. Inside the GLP-1 price war. Novartis inks $1B biobucks deal. UCB/Biogen lupus drug. Lilly Alzheimer’s drug approved in Japan. See more on our front page

Rapastinel Is a FAILURE just like Saunders and AGN


<



















What about territories that already have a CNS2 in place? Those that have CNS2 overlap now have three reps calling on high volume psychiatrists with same drugs and offices hate it